Comparative toxicokinetics of low-viscosity mineral oil in Fischer 344 rats, Sprague-Dawley rats, and humans--implications for an Acceptable Daily Intake (ADI)

Regul Toxicol Pharmacol. 2012 Jun;63(1):69-77. doi: 10.1016/j.yrtph.2012.02.014. Epub 2012 Mar 8.

Abstract

Oral repeated-dose studies with low-viscosity mineral oils showed distinct species and strain differences, which are hypothesized to be due to differences in bioavailability, with Fischer 344 rats being more susceptible than Sprague-Dawley rats or dogs. Sensitive analytical methodology was developed for accurate measurement of low levels of mineral hydrocarbons and applied in single-dose toxicokinetics studies in rats and humans. Fischer 344 rats showed a 4-fold higher AUC(0-∞) and consistently higher blood and liver concentrations were found than Sprague-Dawley rats. Hepatic mineral hydrocarbon concentration tracked the blood concentration in both strains, indicating that blood concentrations can serve as functional surrogate measure for hepatic concentrations. In human volunteers receiving 1mg/kg body weight of low-viscosity white oil, all blood concentrations of mineral hydrocarbons were below the detection limit. Comparison with threshold blood concentrations associated with NOAELs in both rat strains, indicate that the margin-of-exposure is at least 37-fold. Using an internal dose metric rather than applied dose reduces the uncertainty around the temporary ADI considerably since it intrinsically accounts for intra- and inter-species differences. The current data support replacement of the temporary ADI of 0.01 mg/kg/day by a (permanent) ADI of at least 1.0mg/kg/day for low- and medium-viscosity mineral oils.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adult
  • Animals
  • Area Under Curve
  • Female
  • Gas Chromatography-Mass Spectrometry / methods
  • Humans
  • Hydrocarbons / blood
  • Liver / drug effects
  • Liver / metabolism
  • Liver / pathology
  • Mineral Oil / pharmacokinetics*
  • Mineral Oil / toxicity*
  • No-Observed-Adverse-Effect Level
  • Organ Size / drug effects
  • Rats
  • Rats, Inbred F344
  • Rats, Sprague-Dawley
  • Species Specificity
  • Young Adult

Substances

  • Hydrocarbons
  • Mineral Oil